G2GBIO, Inc.
Founded in 2017 and listed on KOSDAQ in 2025, G2GBIO is a long-acting microsphere platform company with multiple licensing deals including one with Boehringer Ingelheim.
As of 2026-10-10, G2GBIO, Inc. has 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2023 (Phase 1 2)
- Phase 1GB-50012023-10-13
1 trial site
- Phase 1GB-60022023-09-18
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Completed · 2025-08 · NCT07799090
Phase 1 · Unknown · 2024-01 · NCT06127368
Phase 1 · Completed · 2023-10 · NCT06095973
Phase 1 · Completed · 2022-08 · NCT05525780
R&D and key agreements
Source: DART corporate disclosureGB-7001 · 비만/당뇨 · 비임상 · A long-acting diabetes/obesity treatment designed for about one month of drug release using the company's microsphere platform.
GB-5001 · 치매 · 임상1상 완료(캐나다), 임상1상 완료(국내), 다회용량상승시험(MAD) 진행중(국내) · A one-month long-acting dementia treatment, licensed out to Korea Pharma Humedix in October 2022.
GB-6002 · 수술후통증조절 · 임상1상 완료(국내) · A postoperative pain treatment with drug release lasting three days or more.
GB-5112 · 치매 · 독성시험 완료
GB-5021 · 조현병 · 제형개발 완료
GB-6201/3 · 탈모 · 독성시험 완료
GB-7101/3 · 전립선암/성조숙증 · 제형개발 완료
GH-001 · B형간염 · 제형개발 진행중 · A three-month long-acting hepatitis B antiviral injectable, licensed out to Hanwha Pharma in April 2022.
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Pharmacokinetic Evaluation of GB-5001, a Long-Acting Injectable Formulation of Donepezil, in Healthy Korean Participants: Population Pharmacokinetics with Phase 1 Study.
Pharmaceutics · 2025-11 · Park YC, Seol E, Lee J 외 3
- Population Pharmacokinetic Modeling and Simulation for Dose Optimization of GB-5001, a Long-Acting Intramuscular Injection of Donepezil, in Healthy Participants.
Neurology and therapy · 2024-10 · Khwarg J, Lee H, Yu KS 외 2
- Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice.
Molecular brain · 2022-07 · Choi HJ, Park JH, Jeong YJ 외 9
- Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling.
International journal of molecular sciences · 2021-09 · Kim J, Lee HJ, Park SK 외 6
- Recent Progress in Drug Release Testing Methods of Biopolymeric Particulate System.
Pharmaceutics · 2021-08 · Kim Y, Park EJ, Kim TW 외 1
Patents
KIPRIS · applicant-matchedPCT · Published · 2026-01 · Application PCT/KR2026/001442
Published · 2026-01 · Application 1020260014220
Published · 2026-01 · Application 1020260009232
PCT · Published · 2026-01 · Application PCT/KR2026/000485
PCT · Published · 2026-01 · Application PCT/KR2026/000483
Published · 2026-01 · Application 1020260003890
Published · 2026-01 · Application 1020260003797
Published · 2025-10 · Application 1020250149095
Published · 2025-06 · Application 1020250087212
Published · 2025-06 · Application 1020250087396
Show 97 more patents
PCT · Published · 2025-06 · Application PCT/KR2025/009260
PCT · Published · 2025-06 · Application PCT/KR2025/009233
Published · 2025-05 · Application 1020250061469
Published · 2025-04 · Application 1020250053330
PCT · Published · 2025-03 · Application PCT/KR2025/003675
Registered · 2025-03 · Application 1020250036868
Published · 2024-12 · Application 1020240183066
Registered · 2024-08 · Application 1020240102603
US · Published · 2024-07 · Application 18764541
CN · Published · 2024-06 · Application 202480050836.4
CN · Published · 2024-06 · Application 202480050827.5
EP · Published · 2024-06 · Application 24815946.9
EP · Published · 2024-06 · Application 24815948.5
PCT · Published · 2024-06 · Application PCT/KR2024/007594
PCT · Published · 2024-06 · Application PCT/KR2024/007596
Registered · 2024-06 · Application 1020240072693
Registered · 2024-06 · Application 1020240072689
US · Published · 2024-05 · Application 18654262
Published · 2024-02 · Application 1020240019929
Published · 2024-02 · Application 1020240019931
Published · 2024-02 · Application 1020240019930
Published · 2024-02 · Application 1020240019928
Registered · 2023-11 · Application 1020230153012
CN · Published · 2023-11 · Application 202380084019.6
US · Published · 2023-11 · Application 19125368
PCT · Published · 2023-11 · Application PCT/KR2023/017791
CN · Published · 2023-09 · Application 202380081006.3
PCT · Published · 2023-09 · Application PCT/KR2023/014929
Rejected · 2023-09 · Application 1020230129812
CN · Published · 2023-09 · Application 202380076927.0
PCT · Published · 2023-09 · Application PCT/KR2023/013112
PCT · Published · 2023-07 · Application PCT/KR2023/010619
Registered · 2023-07 · Application 1020230095626
CN · Published · 2023-07 · Application 202380063876.8
US · Published · 2023-07 · Application 18881366
EP · Published · 2023-07 · Application 23835845.1
PCT · Published · 2023-07 · Application PCT/KR2023/009535
CN · Published · 2023-06 · Application 202380060930.3
CN · Published · 2023-06 · Application 202380049046.X
US · Published · 2023-06 · Application 18878204
EP · Published · 2023-06 · Application 23827572.1
PCT · Published · 2023-06 · Application PCT/KR2023/008786
PCT · Published · 2023-06 · Application PCT/KR2023/008797
PCT · Published · 2023-06 · Application PCT/KR2023/008798
Registered · 2023-06 · Application 1020230081492
Registered · 2023-06 · Application 1020230081447
Registered · 2023-06 · Application 1020230081466
Registered · 2023-05 · Application 1020230059471
Registered · 2023-05 · Application 1020230059478
CN · Published · 2022-11 · Application 202280087985.9
EP · Published · 2022-11 · Application 22890484.3
PCT · Published · 2022-11 · Application PCT/KR2022/017384
Registered · 2022-11 · Application 1020220147404
Registered · 2022-11 · Application 1020220147435
Registered · 2022-08 · Application 1020220096873
Registered · 2022-03 · Application 1020220039981
Rejected · 2022-03 · Application 1020220029577
Rejected · 2021-05 · Application 1020210068590
CN · Published · 2021-02 · Application 202180027937.6
US · Registered · 2021-02 · Application 17904133
EP · Registered · 2021-02 · Application 21754621.7
PCT · Published · 2021-02 · Application PCT/KR2021/001928
Expired · 2021-02 · Application 1020210020164
US · Published · 2020-07 · Application 17625831
EP · Published · 2020-07 · Application 20840297.4
PCT · Published · 2020-07 · Application PCT/KR2020/009221
Rejected · 2020-07 · Application 1020200086399
CN · Published · 2019-12 · Application 201980092245.2
US · Registered · 2019-12 · Application 17312061
EP · Published · 2019-12 · Application 19900868.1
PCT · Published · 2019-12 · Application PCT/KR2019/017905
Registered · 2019-12 · Application 1020190169203
CN · Published · 2019-01 · Application 201980018358.8
CN · Published · 2019-01 · Application 201980018465.0
US · Published · 2019-01 · Application 16960379
US · Registered · 2019-01 · Application 16960366
EP · Registered · 2019-01 · Application 19738756.6
EP · Registered · 2019-01 · Application 19738380.5
PCT · Published · 2019-01 · Application PCT/KR2019/000404
PCT · Published · 2019-01 · Application PCT/KR2019/000403
JP · Published · 2019-01 · Application 32538583
Registered · 2019-01 · Application 1020190003524
Registered · 2019-01 · Application 1020190003525
Registered · 2019-01 · Application 1020190003526
CN · Published · 2018-11 · Application 201880029854.9
CN · Published · 2018-11 · Application 201880037391.0
US · Published · 2018-11 · Application 16494748
US · Registered · 2018-11 · Application 16495825
EP · Published · 2018-11 · Application 22194040.6
EP · Published · 2018-11 · Application 18882842.0
EP · Registered · 2018-11 · Application 18883786.8
PCT · Published · 2018-11 · Application PCT/KR2018/015119
PCT · Published · 2018-11 · Application PCT/KR2018/015121
JP · Registered · 2018-11 · Application 31570943
JP · Published · 2018-11 · Application 31566734
Registered · 2018-11 · Application 1020180152917
Registered · 2018-11 · Application 1020180151359
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot52
- GoogleGoogleOther3
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for G2GBIO, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition